Match!
Apostolia Maria Tsimberidou
University of Texas MD Anderson Cancer Center
439Publications
50H-index
8,295Citations
Publications 443
Newest
This open-label, phase I first-in-human study (NCT01915576) of BAY 1125976, a highly specific and potent allosteric inhibitor of AKT1/2, aimed to evaluate the safety, pharmacokinetics, and maximum tolerated dose of BAY 1125976 in patients with advanced solid tumors. Oral dose escalation was investigated with a continuous once daily (QD) treatment (21 days/cycle) and a twice daily (BID) schedule. A dose expansion in 28 patients with hormone receptor-positive metastatic breast cancer, including ni...
Source
Increasing numbers of oncology therapies are being approved based on early-phase single-arm studies. Yet, little is known regarding the use of patient-reported outcomes in single-arm oncology trials testing novel therapies. We examined patient-reported symptom severity and symptom interference with activity- (WAW: work, general activity, walking) and mood-(REM: relations with others, enjoyment of life, mood) related functioning, and their association with factors known to influence symptom sever...
Source
#1Ecaterina E Ileana Dumbrava (University of Texas MD Anderson Cancer Center)H-Index: 3
#2Kavitha Balaji (Lexicon Pharmaceuticals)H-Index: 4
Last.Funda Meric-Bernstam (University of Texas MD Anderson Cancer Center)H-Index: 76
view all 20 authors...
PURPOSEHuman epidermal growth factor receptor 2 (HER2) is an effective therapeutic target in breast and gastric and gastroesophageal junction cancers. However, less is known about the prevalence of...
Source
#1Aung Naing (University of Texas MD Anderson Cancer Center)H-Index: 41
#2Funda Meric-Bernstam (University of Texas MD Anderson Cancer Center)H-Index: 76
Last.Gauri R. Varadhachary (University of Texas MD Anderson Cancer Center)H-Index: 6
view all 20 authors...
Source
#1Apostolia Maria Tsimberidou (University of Texas MD Anderson Cancer Center)H-Index: 50
#2David K. Hong (University of Texas MD Anderson Cancer Center)H-Index: 54
Last.Funda Meric-Bernstam (University of Texas MD Anderson Cancer Center)H-Index: 76
view all 20 authors...
Source
#1Hossein Maymani (University of Texas MD Anderson Cancer Center)H-Index: 2
#2Kenneth R. Hess (University of Texas MD Anderson Cancer Center)H-Index: 77
Last.Vivek Subbiah (University of Texas MD Anderson Cancer Center)H-Index: 25
view all 17 authors...
Source
#1Yanxun Xu (Johns Hopkins University)H-Index: 12
#2Peter Müller (University of Texas at Austin)H-Index: 35
Last.Donald A. Berry (University of Texas MD Anderson Cancer Center)H-Index: 69
view all 4 authors...
1 CitationsSource
#1Timothy A. Yap (University of Texas MD Anderson Cancer Center)H-Index: 23
#2Jordi Rodon Ahnert (University of Texas MD Anderson Cancer Center)H-Index: 1
Last.Funda Meric-Bernstam (University of Texas MD Anderson Cancer Center)H-Index: 76
view all 20 authors...
3014Background: A subset of tumors possess genetic or microenvironmental alterations that render cells dependent on mitochondria oxidative phosphorylation (OXPHOS) for survival. IACS, a potent oral...
Source
#1Heidi D. Klepin (Wake Forest Baptist Medical Center)H-Index: 24
#2Elizabeth Garrett-Mayer (MUSC: Medical University of South Carolina)H-Index: 46
Last.Dawn L. Hershman (CUMC: Columbia University Medical Center)H-Index: 58
view all 16 authors...
e18279Background: CancerLinQ Discovery (CLQD) is a real-world dataset (RWD) derived from electronic health records across the US. This analysis builds on the prior observation of cautioned use of b...
Source
#1Ryan Huey (University of Texas MD Anderson Cancer Center)H-Index: 1
#2Goldy C George (University of Texas MD Anderson Cancer Center)H-Index: 10
Last.David K. Hong (University of Texas MD Anderson Cancer Center)H-Index: 54
view all 17 authors...
e18383Background: Clinical trials are an important therapeutic option for cancer patients. Although financial burden in cancer treatment is well-described, the financial burden associated with clin...
Source
12345678910